Type 1 diabetes
Metabolicยท 10 reviewed drugsยท 8629 cited findings behind them
What the regulatory reviews cover
The regulatory review documents in this library for Type 1 diabetes include Tresiba, Ryzodeg, Tzield, Lyumjev, Awiqli, Teizeild, Fiasp, LANTUS, Apidra, and Humalog Mix 50/50. These drugs are indicated for various aspects of diabetes mellitus treatment, including improving glycemic control, delaying the decline in endogenous insulin production, and delaying the onset of Stage 3 T1D.
Different drugs were studied in different trials, so the figures are not head-to-head comparisons. For instance, Tresiba showed an HbA1c change from baseline of -0.57. Ryzodeg demonstrated a Day-to-day variability in glucose-lowering effect (AUCGIR,ฯ,SS) (CV%) of 20, compared to 82 for comparator IGlar. Tzield reported a Difference in LSMean change from baseline in C-peptide AUC (log transformed) of 0.13. Teizeild showed a Median time to progression to stage 3 T1D of 49.5 months, versus 24.9 months for placebo.
The drugs โ one cited result each
| Tresiba NOVO | HbA1c change from baseline: -0.57 NOVO โ Tresiba FDA Review (NDA/BLA 203314, 2018), p.31 |
| Ryzodeg Novo Nordisk A S | Day-to-day variability in glucose-lowering effect (AUCGIR,ฯ,SS) (CV%): 20 Novo Nordisk A S โ Ryzodeg EMA EPAR public assessment report, p.37 |
| Tzield PROVENTION BIO INC | Difference in LSMean change from baseline in C-peptide AUC (log transformed): 0.13 PROVENTION BIO INC โ Tzield FDA Review (BLA761183, SUPPL 10,, p.69 |
| Lyumjev Eli Lilly and Company | Documented symptomatic hypoglycaemia (<3.0 mmol/L) rate (LY900014): 6.71 Eli Lilly and Company โ Lyumjev (previously Liumjev) EMA EPA, p.168 |
| Awiqli Novo Nordisk A S | Serious AEs (ONWARDS 2, insulin icodec): 8.4 Novo Nordisk A S โ Awiqli EMA EPAR public assessment report, p.137 |
| Teizeild Sanofi | Median time to progression to stage 3 T1D (Teizeild): 49.5 Sanofi โ Teizeild EMA EPAR public assessment report (EMEA/H/, p.9 |
| Fiasp NOVO | HbA1c treatment difference (meal-time Fiasp vs meal-time NovoLog): -0.17 NOVO โ Fiasp FDA Review (NDA/BLA 208751, 2026), p.9 |
| LANTUS Sanofi | HbA1c adjusted mean change from baseline (Study A): +0.21 Lantus FDA Review, p.19 |
| Apidra Sanofi | HbA1c change from baseline: -0.1 SANOFI AVENTIS US โ Apidra FDA Review (NDA/BLA 021629, 2020), p.38 |
| Humalog Mix 50/50 Eli Lilly and Company | Fasting Blood Glucose (Type 1 diabetes): 209.5 ยฑ 91.6 LILLY โ Humalog Mix 50/50 FDA Review (NDA/BLA 021018, 2020), p.20 |
Different drugs were studied in different trials โ these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs โ searchable, comparable and answerable in plain language โ is in the Metabolic research library โ
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only โ not medical or investment advice.